A 48-year-old woman from Mumbai with a history of poorly controlled diabetes mellitus presents with a 5-month history of cough, hemoptysis, and weight loss. She was treated for pulmonary TB 3 years ago with standard DOTS and was declared cured. She now presents with recurrent TB. Sputum smear microscopy is positive (AFB 3+). Culture and DST reveal resistance to isoniazid, rifampicin, levofloxacin, and amikacin. What is the most likely reason for this pattern of drug resistance?

Explanation

## Clinical Scenario Analysis This patient presents with **recurrent TB** (TB occurring after a previous episode declared cured). The DST pattern shows resistance to: - **First-line agents:** Isoniazid (INH) and rifampicin (RIF) → MDR-TB - **Second-line agents:** Levofloxacin (fluoroquinolone) and amikacin (injectable) → XDR-TB The critical clue is the **3-year interval** between cure and recurrence, combined with the **XDR pattern**. ## Differential Diagnosis of Recurrent TB | Feature | Reactivation | Reinfection | |---------|--------------|-------------| | **Time interval** | Usually < 2 years | Can be > 2 years | | **Reason for recurrence** | Incomplete sterilization of original focus | New exposure to TB case in community | | **Drug resistance pattern** | Same as original strain (or acquired during treatment) | May be different from original strain | | **Radiological findings** | Often same location as original | May be different location | | **Epidemiology** | More common in immunocompromised | More common in high TB prevalence areas | | **This case** | Original was drug-susceptible (DOTS-cured) | ✓ New XDR strain from community | ## Why Reinfection with XDR Is Most Likely **Key Point:** The original TB episode was treated with standard DOTS and declared cured. This implies the original strain was **drug-susceptible**. If it were MDR-TB, DOTS would have failed (as in Question 1), and the patient would not have been declared cured. **High-Yield:** A patient cured of drug-susceptible TB who later develops **XDR-TB** has almost certainly been **reinfected** with a new, highly resistant strain from the community, not reactivation of the original strain. **Clinical Pearl:** In high-burden TB settings (e.g., Mumbai), the prevalence of XDR-TB in the community is rising. A previously cured patient with poor TB contact precautions (e.g., living in crowded conditions, diabetes as a risk factor for severe TB) is at risk of reinfection with a more resistant strain. ## Why Other Options Are Incorrect 1. **Reactivation with acquired resistance:** Even if the original strain were MDR-TB, acquiring resistance to *both* a fluoroquinolone *and* an injectable during a single treatment course is extremely rare. The original strain was drug-susceptible (DOTS-cured), so this does not apply. 2. **Inadequate dosing of second-line drugs:** The original treatment was standard DOTS (first-line only), not second-line therapy. There is no history of second-line drug exposure, so inadequate dosing of second-line agents cannot explain the XDR pattern. 3. **Spontaneous mutation during latency:** Mycobacteria do not spontaneously acquire resistance to multiple drug classes during dormancy. Resistance emerges under selective pressure (inadequate drug concentration). A latent focus of drug-susceptible TB would remain drug-susceptible.